Remove Containment Remove Doctors Remove Immune Response
article thumbnail

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

The Pharma Data

Chimeric PD-1 T-cells also release cytokines to further initiate immune responses to eradicate the tumor cells. This press release contains forward-looking statements that involve substantial risks and uncertainties. Link to her profile: [link]. Dr. Barber also serves on Kiromic’s Scientific Advisory Board.

In-Vivo 40
article thumbnail

Scans Reveal How COVID-19 Can Harm the Brain

The Pharma Data

31, 2020 — Blood vessel damage and inflammation in the brains of deceased COVID-19 patients suggest the damage is not caused by the virus, but the body’s immune response to it. The spots were surrounded by T cells — signs of an immune response. THURSDAY, Dec. Researchers from the U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Electromedical Technologies Produces $4.2 Million in Device Inventory to Meet Demand

The Pharma Data

Matthew Wolfson, Founder and CEO of EMED, commented, “Every day more doctors and patients are realizing the importance of using methods that will have a positive effect in reducing pain without having negative effects on the immune system, especially in today’s pandemic environment. For more information, visit www.electromedtech.com.

article thumbnail

Necessity Is the Mother of Innovation: Key Trends and Predictions from Biotech Showcase Digital After an Unprecedented Year That Drove Momentous Changes in Healthcare

Pharma Marketing Network

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccine 52
article thumbnail

Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

The Pharma Data

CITYSCAPE provides the first evidence that targeting both immune inhibitory receptors, TIGIT and PD-L1, may enhance anti-tumor activity by potentially amplifying the immune response. “We TIGIT and PD-L1 are proteins that play a role in suppression of the immune system. Report side effects to Genentech at (888) 835-2555.

article thumbnail

COVID-19 Pandemic Coverage

XTalks

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. It was recently reported that the addition of an adjuvant to their vaccine led to enhanced immune responses that exceeded responses in convalescent serum from symptomatic COVID-19 patients. That’s if Russia doesn’t get its hands on it first.

Vaccine 92